The failures of anti-toll-like receptor 4 antibody, recombinant activated protein C, and anti-TNF-α therapies in clinical trials require a rethinking of sepsis’ pathophysiology and therapeutic strategies (8, 55–60). This evidence concerns the gene TLR4 and Sepsis.